Details for New Drug Application (NDA): 022224
✉ Email this page to a colleague
NDA 022224 describes TRILIPIX, which is a drug marketed by Abbvie and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the TRILIPIX profile page.
The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.
The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.
Summary for 022224
| Tradename: | TRILIPIX |
| Applicant: | Abbvie |
| Ingredient: | choline fenofibrate |
| Patents: | 1 |
Suppliers and Packaging for NDA: 022224
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TRILIPIX | choline fenofibrate | CAPSULE, DELAYED RELEASE;ORAL | 022224 | NDA | AbbVie Inc. | 0074-3161 | 0074-3161-90 | 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0074-3161-90) |
| TRILIPIX | choline fenofibrate | CAPSULE, DELAYED RELEASE;ORAL | 022224 | NDA | AbbVie Inc. | 0074-3162 | 0074-3162-90 | 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0074-3162-90) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, DELAYED RELEASE;ORAL | Strength | EQ 45MG FENOFIBRIC ACID | ||||
| Approval Date: | Dec 15, 2008 | TE: | AB | RLD: | Yes | ||||
| Patent: | 7,259,186 | Patent Expiration: | Jan 7, 2025 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, DELAYED RELEASE;ORAL | Strength | EQ 135MG FENOFIBRIC ACID | ||||
| Approval Date: | Dec 15, 2008 | TE: | AB | RLD: | Yes | ||||
| Patent: | 7,259,186 | Patent Expiration: | Jan 7, 2025 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Complete Access Available with Subscription
